Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 20%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure is expected to have strong growth potential, with increasing demand for its flagship product Optune in both the United States and international markets. This is supported by its recent financial performance, with a decrease in operating expenses and a strong product launch for Optune Pax in the pancreatic cancer market. Additionally, the company has a robust pipeline that includes potential collaborations and clinical trials for other indications, such as earlier line use of TTFields with novel therapies in pancreatic cancer and potential expansion into the metastatic setting. Overall, the company's positive financial outlook, strong product portfolio, and potential for growth make it an attractive investment opportunity.

Bears say

NovoCure is facing challenges in maintaining its growth as it failed to achieve statistically significant improvement in its primary endpoint of OS for TRIDENT, its Phase 3 trial for newly diagnosed GBM. The company's early launch metrics for Optune Pax look promising but may face competition from rival company RVMD. Additionally, the lung cancer market may be more incremental in terms of revenue growth due to competition from targeted therapies and limited treatment duration.

Novocure (NVCR) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 20% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 5 analysts, Novocure (NVCR) has a Buy consensus rating as of Aug 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.